SVB Leerink analyst Puneet Souda lowered his price target for Myriad Genetics to $28 from $37 and maintained a Market Perform rating, given that its core hereditary cancer franchise continues to see competitive and pricing pressures while its broader testing franchise including GeneSight is unable to shore up the decline. Myriad negatively surprised in yet another quarter, Souda tells investors in a research note, adding that he believes the stock will likely trade down as expectations are reset after what seems to be a string of quarters with negative surprises including impact from Lab Benefit Managers, FDA inquiry, GeneSight ADHD discontinuation and coding changes in its core hereditary business.